Developing New Approaches to Treat Heart Disease
The Mercola laboratory is focused on developing new therapies for cardiovascular disease. Cardiovascular disease, including heart failure, remains a major cause of human mortality worldwide despite advances in clinical management. Our research combines in vitro disease models using cardiovascular cells generated from induced pluripotent stem cells (iPSCs) with high throughput screening to define disease mechanisms, identify drug targets and develop drug leads. Since iPSCs are derived from patient biopsies, these cells make it possible to visualize the effect of individual patient genetics on disease, and develop new and effective drugs.
Dr. Mercola is Professor of Cardiovascular Medicine and a member of the Stanford Cardiovascular Institute. He trained at the Dana-Farber Cancer Institute in Boston and Harvard Medical School. He was on the faculty at Harvard Medical School and then at the Sanford-Burnham-Prebys Medical Discovery Institute and the Department of Bioengineering at the University of California, San Diego prior to relocating to Stanford in 2015. The laboratory is funded by research grants from the National Institutes of Health (NIH), the California Institute for Regenerative Medicine and the Fondation Leducq.
Human cardiomyocytes derived from induced pluripotent stem cells (iPSCs) made from a healthy individual.
- Sharma, A., et al. (2017). High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci Transl Med 9, 377.
- Molokanova, E., et al. (2017). Bringing new dimensions to drug discovery screening: impact of cellular stimulation technologies. Drug Discov Today 1359-6446(17)30061-2.
- Crespo, R., et al. (2017). Effect of geraniol on rat cardiomyocytes and its potential use as a cardioprotective natural compound. Life Sci S0024-3205(17)30031-0.
- Ma, Y., et al. (2016). The CSRP2BP histone acetyltransferase drives smooth muscle gene expression. Nucleic Acids Res gkw1227.
- Shen, X., et al. (2016). miR-322/-503 cluster is expressed in the earliest cardiac progenitor cells and drives cardiomyocyte specification. Proc Natl Acad Sci U S A 133, 34.
- Liu, Y., et al. (2016). The All-Chemical Approach: A Solution for Converting Fibroblasts Into Myocytes. Circ Res 119, 4.
- Diaz-Trelles, et al. (2016). Notch-independent RBPJ controls angiogenesis in the adult heart. Nat Commun 7, 12088.
- Del Alamo, J.C., et al. (2016). High throughput physiological screening of iPSC-derived cardiomyocytes for drug development. Biochim Biophys Acta 1863, 1717-1727.
- Zaretski, A.V., et al. (2016). Metallic Nanoislands on Graphene as Highly Sensitive Transducers of Mechanical, Biological, and Optical Signals. Nano Lett 16, 1375-1380.